A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study
- 1 May 2007
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 105 (2) , 508-516
- https://doi.org/10.1016/j.ygyno.2007.01.019
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Sex steroid-dependent angiogenesis in uterine endometrial cancersThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- VEGF and Its Receptors (flt-1 and KDR/flk-1) as Prognostic Indicators in Endometrial CarcinomaTumor Biology, 2005
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Cytosol Vascular Endothelial Growth Factor in Endometrial Carcinoma: Correlation with Disease-Free SurvivalGynecologic Oncology, 2001
- Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levelsPublished by Wolters Kluwer Health ,2000
- Prognostic Significance of Vascular Endothelial Growth Factor and Its Receptors in Endometrial CarcinomaGynecologic Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Angiogenesis in Endometrial Hyperplasia and Stage I Endometrial CarcinomaPublished by Wolters Kluwer Health ,1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994